Santen Pharmaceutical Announces Results of Overseas Clinical Trials for Glaucoma Drug Candidates DE-092 and DE-085.Tokyo, Japan, Feb 15, 2006 - (JCN) - Santen Pharmaceutical announced on February 14 the preliminary results of overseas clinical trials of DE- de- word element [L.], down; from; sometimes negative or privative, and often intensive. de- pref. 1. Do or make the opposite of; reverse: decomposition. 2. 092 (olmesartan) and DE-085 (tafluprost), two drug candidates for the treatment of glaucoma. Santen Incorporated, Santen's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in the US, has conducted an early phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II of DE-092. Although the eye pressure-lowering effect was observed, the results failed to indicate an evident correlation between dose-response and use of the agent. In the meantime Adv. 1. in the meantime - during the intervening time; "meanwhile I will not think about the problem"; "meantime he was attentive to his other interests"; "in the meantime the police were notified" meantime, meanwhile , Santen Oy, Santen's wholly owned subsidiary in Finland, has conducted a phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of DE-085. Again, the agent demonstrated an eye pressure-lowering effect, but any favorable result was obtained from a non-inferiority study in which DE-085 was compared with latanoprost. In accordance with the aforementioned results, Santen plans to reconsider its development strategies for DE-092 and DE-085 in the US and Europe. In Japan, however, the company will proceed with research on the two agents as previously scheduled. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion